Long-Term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: A systematic review and meta-Analysis

Masahiro Yoshikawa, Osamu Takase, Taro Tsujimura, Etsuko Sano, Matsuhiko Hayashi, Tsuyoshi Takato, Keiichi Hishikawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Hypercalcemia and hyperparathyroidism in patients receiving maintenance hemodialysis (MHD) can cause the progression of cardiovascular diseases (CVD) and mineral bone disorders (MBD). The KDIGO recommends the dialysates with a calcium (Ca) concentration of 1.25-1.5 mmol/L for MHD treatments, but the optimal concentration remains controversial. Here, we conducted a systematic review and a meta-Analysis of seven randomized controlled trials examining a total of 622 patients to investigate the optimal concentration for MHD for 6 months or longer. The dialysates with a low Ca concentration (1.125 or 1.25 mmol/L) significantly lowered the serum Ca and raised the intact parathyroid hormone levels by 0.52 mg/dL (95% confidence interval, 0.20-0.85) and 39.59 pg/mL (14.80-64.38), respectively, compared with a high Ca concentration (1.50 or 1.75 mmol/L). Three studies showed that a low concentration was preferred for lowering arterial calcifications or atherosclerosis in different arteries, but one study showed that coronary arterial calcifications increased with a low concentration. Two studies showed contradictory outcomes in terms of MBD. Our meta-Analysis showed that a dialysate with a low Ca concentration lowered the serum Ca levels in patients receiving long-Term MHD, but further studies are needed to determine the optimal Ca concentration in terms of CVD and MBD.

Original languageEnglish
Article number5310
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Dialysis Solutions
Renal Dialysis
Meta-Analysis
Maintenance
Calcium
Serum
Minerals
Bone and Bones
Therapeutics
Cardiovascular Diseases
Hyperparathyroidism
Hypercalcemia
Parathyroid Hormone
Atherosclerosis
Randomized Controlled Trials
Arteries
Confidence Intervals

ASJC Scopus subject areas

  • General

Cite this

Long-Term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments : A systematic review and meta-Analysis. / Yoshikawa, Masahiro; Takase, Osamu; Tsujimura, Taro; Sano, Etsuko; Hayashi, Matsuhiko; Takato, Tsuyoshi; Hishikawa, Keiichi.

In: Scientific Reports, Vol. 8, No. 1, 5310, 01.12.2018.

Research output: Contribution to journalArticle

Yoshikawa, Masahiro ; Takase, Osamu ; Tsujimura, Taro ; Sano, Etsuko ; Hayashi, Matsuhiko ; Takato, Tsuyoshi ; Hishikawa, Keiichi. / Long-Term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments : A systematic review and meta-Analysis. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{a0e2a9ca571446c5ab35654f12d2db94,
title = "Long-Term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: A systematic review and meta-Analysis",
abstract = "Hypercalcemia and hyperparathyroidism in patients receiving maintenance hemodialysis (MHD) can cause the progression of cardiovascular diseases (CVD) and mineral bone disorders (MBD). The KDIGO recommends the dialysates with a calcium (Ca) concentration of 1.25-1.5 mmol/L for MHD treatments, but the optimal concentration remains controversial. Here, we conducted a systematic review and a meta-Analysis of seven randomized controlled trials examining a total of 622 patients to investigate the optimal concentration for MHD for 6 months or longer. The dialysates with a low Ca concentration (1.125 or 1.25 mmol/L) significantly lowered the serum Ca and raised the intact parathyroid hormone levels by 0.52 mg/dL (95{\%} confidence interval, 0.20-0.85) and 39.59 pg/mL (14.80-64.38), respectively, compared with a high Ca concentration (1.50 or 1.75 mmol/L). Three studies showed that a low concentration was preferred for lowering arterial calcifications or atherosclerosis in different arteries, but one study showed that coronary arterial calcifications increased with a low concentration. Two studies showed contradictory outcomes in terms of MBD. Our meta-Analysis showed that a dialysate with a low Ca concentration lowered the serum Ca levels in patients receiving long-Term MHD, but further studies are needed to determine the optimal Ca concentration in terms of CVD and MBD.",
author = "Masahiro Yoshikawa and Osamu Takase and Taro Tsujimura and Etsuko Sano and Matsuhiko Hayashi and Tsuyoshi Takato and Keiichi Hishikawa",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-23658-y",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Long-Term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments

T2 - A systematic review and meta-Analysis

AU - Yoshikawa, Masahiro

AU - Takase, Osamu

AU - Tsujimura, Taro

AU - Sano, Etsuko

AU - Hayashi, Matsuhiko

AU - Takato, Tsuyoshi

AU - Hishikawa, Keiichi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Hypercalcemia and hyperparathyroidism in patients receiving maintenance hemodialysis (MHD) can cause the progression of cardiovascular diseases (CVD) and mineral bone disorders (MBD). The KDIGO recommends the dialysates with a calcium (Ca) concentration of 1.25-1.5 mmol/L for MHD treatments, but the optimal concentration remains controversial. Here, we conducted a systematic review and a meta-Analysis of seven randomized controlled trials examining a total of 622 patients to investigate the optimal concentration for MHD for 6 months or longer. The dialysates with a low Ca concentration (1.125 or 1.25 mmol/L) significantly lowered the serum Ca and raised the intact parathyroid hormone levels by 0.52 mg/dL (95% confidence interval, 0.20-0.85) and 39.59 pg/mL (14.80-64.38), respectively, compared with a high Ca concentration (1.50 or 1.75 mmol/L). Three studies showed that a low concentration was preferred for lowering arterial calcifications or atherosclerosis in different arteries, but one study showed that coronary arterial calcifications increased with a low concentration. Two studies showed contradictory outcomes in terms of MBD. Our meta-Analysis showed that a dialysate with a low Ca concentration lowered the serum Ca levels in patients receiving long-Term MHD, but further studies are needed to determine the optimal Ca concentration in terms of CVD and MBD.

AB - Hypercalcemia and hyperparathyroidism in patients receiving maintenance hemodialysis (MHD) can cause the progression of cardiovascular diseases (CVD) and mineral bone disorders (MBD). The KDIGO recommends the dialysates with a calcium (Ca) concentration of 1.25-1.5 mmol/L for MHD treatments, but the optimal concentration remains controversial. Here, we conducted a systematic review and a meta-Analysis of seven randomized controlled trials examining a total of 622 patients to investigate the optimal concentration for MHD for 6 months or longer. The dialysates with a low Ca concentration (1.125 or 1.25 mmol/L) significantly lowered the serum Ca and raised the intact parathyroid hormone levels by 0.52 mg/dL (95% confidence interval, 0.20-0.85) and 39.59 pg/mL (14.80-64.38), respectively, compared with a high Ca concentration (1.50 or 1.75 mmol/L). Three studies showed that a low concentration was preferred for lowering arterial calcifications or atherosclerosis in different arteries, but one study showed that coronary arterial calcifications increased with a low concentration. Two studies showed contradictory outcomes in terms of MBD. Our meta-Analysis showed that a dialysate with a low Ca concentration lowered the serum Ca levels in patients receiving long-Term MHD, but further studies are needed to determine the optimal Ca concentration in terms of CVD and MBD.

UR - http://www.scopus.com/inward/record.url?scp=85044539143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044539143&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-23658-y

DO - 10.1038/s41598-018-23658-y

M3 - Article

AN - SCOPUS:85044539143

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 5310

ER -